Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,818 | 265 | 49.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,500 | 2 | 25.9% |
| Consulting Fee | $1,995 | 1 | 20.7% |
| Education | $336.75 | 22 | 3.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eisai Inc. | $4,495 | 3 | $0 (2021) |
| PFIZER INC. | $618.88 | 43 | $0 (2023) |
| Amgen Inc. | $493.93 | 20 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $463.93 | 32 | $0 (2018) |
| Genentech USA, Inc. | $317.30 | 19 | $0 (2018) |
| Millennium Pharmaceuticals, Inc. | $303.96 | 9 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $246.04 | 14 | $0 (2018) |
| INSYS Therapeutics Inc | $213.64 | 11 | $0 (2018) |
| Incyte Corporation | $189.64 | 10 | $0 (2017) |
| Merck Sharp & Dohme LLC | $184.82 | 10 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $48.36 | 3 | Merck Sharp & Dohme LLC ($18.09) |
| 2023 | $102.27 | 6 | PFIZER INC. ($46.74) |
| 2022 | $133.36 | 6 | PFIZER INC. ($63.98) |
| 2021 | $2,620 | 11 | Eisai Inc. ($2,500) |
| 2020 | $1,995 | 1 | Eisai Inc. ($1,995) |
| 2019 | $73.05 | 4 | Allergan Inc. ($52.67) |
| 2018 | $608.77 | 28 | Takeda Pharmaceuticals U.S.A., Inc. ($119.08) |
| 2017 | $4,069 | 231 | E.R. Squibb & Sons, L.L.C. ($446.39) |
All Payment Transactions
290 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Merck Sharp & Dohme LLC | WELIREG (Drug) | Education | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 05/29/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Education | In-kind items and services | $16.53 | General |
| Category: Genetically Defined Disease | ||||||
| 02/14/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $13.74 | General |
| Category: Oncology | ||||||
| 10/03/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $20.91 | General |
| Category: Oncology | ||||||
| 04/21/2023 | Boston Scientific Corporation | WaveWriter Alpha Prime 16 (Device) | Food and Beverage | In-kind items and services | $19.62 | General |
| Category: WaveWriter Alpha_NMD | ||||||
| 03/02/2023 | PFIZER INC. | LORBRENA (Drug) | Education | In-kind items and services | $15.50 | General |
| Category: ONCOLOGY | ||||||
| 02/07/2023 | Boston Scientific Corporation | LUX-Dx Insertable Cardiac Monitor (Device) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: LUX-Dx_CRM | ||||||
| 02/04/2023 | PFIZER INC. | IBRANCE (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $17.90 | General |
| Category: ONCOLOGY | ||||||
| 01/06/2023 | PFIZER INC. | INLYTA (Drug) | Education | In-kind items and services | $13.34 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2022 | Takeda Pharmaceuticals U.S.A., Inc. | ICLUSIG (Drug) | Education | In-kind items and services | $32.75 | General |
| Category: ONCOLOGY | ||||||
| 09/30/2022 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $25.12 | General |
| Category: ONCOLOGY | ||||||
| 08/11/2022 | Myriad Genetic Laboratories, Inc. | myRisk (Device) | Food and Beverage | Cash or cash equivalent | $17.50 | General |
| Category: Germline DNA Sequencing Hereditary Cancer and Rearrangement Analysis | ||||||
| 03/31/2022 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $19.13 | General |
| Category: RESPIRATORY | ||||||
| 01/14/2022 | PFIZER INC. | INLYTA (Drug) | Education | In-kind items and services | $13.34 | General |
| Category: ONCOLOGY | ||||||
| 01/07/2022 | PFIZER INC. | INLYTA (Drug) | Education | In-kind items and services | $25.52 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2021 | PFIZER INC. | INLYTA (Drug), BAVENCIO, LORBRENA | Food and Beverage | In-kind items and services | $23.34 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2021 | PFIZER INC. | INLYTA (Drug) | Education | In-kind items and services | $25.52 | General |
| Category: ONCOLOGY | ||||||
| 10/22/2021 | Eisai Inc. | Lenvima (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: Oncology | ||||||
| 10/21/2021 | PFIZER INC. | INLYTA (Drug) | Education | In-kind items and services | $7.60 | General |
| Category: ONCOLOGY | ||||||
| 08/11/2021 | Eisai Inc. | Lenvima (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,000.00 | General |
| Category: Oncology | ||||||
| 07/21/2021 | PFIZER INC. | INLYTA (Drug) | Food and Beverage | In-kind items and services | $22.82 | General |
| Category: ONCOLOGY | ||||||
| 07/19/2021 | PFIZER INC. | INLYTA (Drug) | Education | In-kind items and services | $8.16 | General |
| Category: ONCOLOGY | ||||||
| 07/12/2021 | PFIZER INC. | INLYTA (Drug) | Education | In-kind items and services | $8.20 | General |
| Category: ONCOLOGY | ||||||
| 07/09/2021 | PFIZER INC. | INLYTA (Drug) | Education | In-kind items and services | $8.16 | General |
| Category: ONCOLOGY | ||||||
| 04/21/2021 | PFIZER INC. | INLYTA (Drug) | Education | In-kind items and services | $8.16 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 869 | 1,397 | $518,360 | $92,679 |
| 2022 | 9 | 1,123 | 2,279 | $970,360 | $187,407 |
| 2021 | 9 | 1,117 | 2,561 | $1.2M | $241,754 |
| 2020 | 11 | 1,150 | 2,780 | $1.1M | $210,496 |
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 337 | 659 | $263,600 | $46,346 | 17.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 98 | 151 | $80,785 | $17,096 | 21.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 68 | 68 | $51,000 | $9,802 | 19.2% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 205 | 326 | $55,420 | $8,644 | 15.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 62 | 62 | $37,200 | $6,196 | 16.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 42 | 47 | $12,925 | $1,941 | 15.0% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 27 | 30 | $8,250 | $1,344 | 16.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 30 | 54 | $9,180 | $1,310 | 14.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 425 | 1,225 | $490,000 | $91,987 | 18.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 217 | 492 | $263,220 | $56,913 | 21.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 88 | 88 | $66,000 | $12,281 | 18.6% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 123 | 155 | $62,000 | $9,836 | 15.9% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 95 | 109 | $29,975 | $5,671 | 18.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 47 | 47 | $28,200 | $5,147 | 18.3% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2022 | 66 | 78 | $13,260 | $2,314 | 17.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 35 | 54 | $9,180 | $1,637 | 17.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 27 | 31 | $8,525 | $1,620 | 19.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 294 | 882 | $471,870 | $107,914 | 22.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 353 | 954 | $381,600 | $71,929 | 18.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 206 | 357 | $142,800 | $28,239 | 19.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 117 | 117 | $87,750 | $16,357 | 18.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 38 | 98 | $16,660 | $6,065 | 36.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 18 | 52 | $13,000 | $4,462 | 34.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 41 | 41 | $24,600 | $3,256 | 13.2% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 36 | 44 | $12,100 | $2,147 | 17.7% |
About Dr. Sang Ahn, M.D
Dr. Sang Ahn, M.D is a Specialist healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/28/2007. The National Provider Identifier (NPI) number assigned to this provider is 1568581759.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sang Ahn, M.D has received a total of $9,650 in payments from pharmaceutical and medical device companies, with $48.36 received in 2024. These payments were reported across 290 transactions from 37 companies. The most common payment nature is "Food and Beverage" ($4,818).
As a Medicare-enrolled provider, Ahn has provided services to 4,259 Medicare beneficiaries, totaling 9,017 services with total Medicare billing of $732,335. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Practice Information
- Specialty Specialist
- Other Specialties Hematology & Oncology
- Location Los Angeles, CA
- Active Since 03/28/2007
- Last Updated 11/27/2023
- Taxonomy Code 174400000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1568581759
Products in Payments
- Lenvima (Drug) $4,495
- OPDIVO (Biological) $411.41
- NINLARO (Drug) $402.48
- XTANDI (Drug) $210.95
- Nplate (Biological) $194.51
- INLYTA (Drug) $191.71
- JAKAFI (Drug) $189.64
- Cabometyx (Drug) $184.80
- GILOTRIF (Drug) $181.94
- Kyprolis (Biological) $168.55
- KEYTRUDA (Biological) $166.73
- Avastin (Biological) $158.40
- Imbruvica (Drug) $155.15
- SYNDROS (Drug) $148.28
- TAGRISSO (Drug) $127.23
- TECENTRIQ (Biological) $114.39
- Xtandi (Drug) $100.78
- Rubraca (Drug) $100.60
- FASLODEX (Drug) $95.99
- IBRANCE (Drug) $93.01
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Los Angeles
Dr. Sanjay Kaul, M.d, M.D
Specialist — Payments: $1.7M
Dr. William Hardy, M.d, M.D
Specialist — Payments: $785,429
Dr. Harmik Soukiasian, M.d, M.D
Specialist — Payments: $691,800
Dr. Ray Matthews, M.d, M.D
Specialist — Payments: $327,799
Dr. Neil Kaplowitz, M.d, M.D
Specialist — Payments: $151,588
Gil Hoftman, M.d., Ph.d, M.D., PH.D
Specialist — Payments: $112,132